Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 16/20 | 0.75 |
| ▸ | HDAC3 | O15379 | 9/20 | 0.75 |
| ▸ | HDAC2 | Q92769 | 9/20 | 0.75 |
| ▸ | HDAC4 | P56524 | 5/20 | 0.75 |
| ▸ | HDAC10 | Q969S8 | 5/20 | 0.75 |
| ▸ | HDAC7 | Q8WUI4 | 4/20 | 0.75 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.75 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.75 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.75 |
| ▸ | HDAC9 | Q9UKV0 | 4/20 | 0.75 |
| ▸ | HDAC5 | Q9UQL6 | 4/20 | 0.75 |
| ▸ | KDM1A | O60341 | 4/20 | 0.74 |
| ▸ | RCOR1 | Q9UKL0 | 2/20 | 0.74 |
| ▸ | NCOR2 | Q9Y618 | 4/20 | 0.65 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL674368 | 0.96 | HDAC1 (0.70) | HDAC1HDAC3HDAC2HDAC4HDAC10 | |
| SCHEMBL674310 | 0.93 | HDAC1 (0.75) | HDAC1HDAC3HDAC2HDAC4HDAC10 | |
| SCHEMBL17073035 | 0.90 | HDAC1 (0.70) | HDAC1HDAC3HDAC2HDAC4HDAC10 | |
| SCHEMBL2412935 | 0.88 | HDAC1 (0.68) | HDAC1HDAC3HDAC2HDAC4HDAC10 | |
| SCHEMBL3813600 | 0.86 | HDAC1 (1.00) | HDAC1HDAC3HDAC2HDAC4HDAC10 | |
| SCHEMBL4258366 | 0.86 | HDAC1 (0.75) | HDAC1HDAC3HDAC2HDAC4HDAC10 | |
| SCHEMBL17073055 | 0.85 | KDM1A (1.00) | HDAC1HDAC3HDAC2HDAC4HDAC10 | |
| SCHEMBL23673796 | 0.85 | HDAC1 (0.69) | HDAC1HDAC3HDAC2HDAC4HDAC10 | |
| SCHEMBL674396 | 0.85 | HDAC1 (0.74) | HDAC1HDAC3HDAC2HDAC4HDAC10 | |
| SCHEMBL18459058 | 0.84 | HDAC1 (0.73) | HDAC1HDAC3HDAC2HDAC4HDAC10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1696898-B1 | ZN 2+ -CHELATING MOTIF-TETHERED SHORT-CHAIN FATTY ACIDS AS A NOVEL CLASS OF HISTONE DEACETYLASE INHIBITORS | UNIV OHIO STATE RES FOUND (US) | 2015-11-18 | — | — | EP | claimed |
| US-9115090-B2 | Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2015-08-25 | — | — | US | claimed |
| US-20070225373-A1 | Zn2Motif-Tethered Short-Chain Fatty Acids as a Novel Class of Histone Deacetylase | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2007-09-27 | — | — | US | claimed |
| EP-1696898-A2 | ZN 24 -CHELATING MOTIF-TETHERED SHORT-CHAIN FATTY ACIDS AS A NOVEL CLASS OF HISTONE DEACETYLASE INHIBITORS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2006-09-06 | — | — | EP | claimed |
| WO-2005055928-A2 | ZN2+ -CHELATING MOTIF-TETHERED SHORT -CHAIN FATTY ACIDS AS A NOVEL CLASS OF HISTONE DEACETYLASE INHIBITORS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2005-06-23 | — | — | WO | claimed |
| EP-1696898-B1 | ZN 2+ -CHELATING MOTIF-TETHERED SHORT-CHAIN FATTY ACIDS AS A NOVEL CLASS OF HISTONE DEACETYLASE INHIBITORS | UNIV OHIO STATE RES FOUND (US) | 2015-11-18 | — | — | EP | disclosed |
| US-9115090-B2 | Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2015-08-25 | — | — | US | disclosed |
| US-8318808-B2 | Zn2+chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2012-11-27 | — | — | US | disclosed |
| US-20110281950-A1 | COMPOSITIONS AND METHODS FOR REDUCING PROLIFERATION AND VIABILITY OF LYMPHOBLASTOID CELLS | BAIOCCHI ROBERT A (US) | 2011-11-17 | — | — | US | disclosed |
| WO-2011143314-A1 | COMPOSITIONS AND METHODS FOR REDUCING PROLIFERATION AND VIABILITY OF LYMPHOBLASTOID CELLS | ARNO THERAPEUTICS, INC (US) | 2011-11-17 | — | — | WO | disclosed |
| US-8026239-B2 | Cell differentiation inducer | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-09-27 | — | — | US | disclosed |
| WO-2011103563-A1 | METHODS AND COMPOSITIONS FOR INHIBITING AND PREVENTING THE GROWTH OF MALIGNANT MAST CELLS | ARNO THERAPEUTICS, INC (US) | 2011-08-25 | — | — | WO | disclosed |
| US-20050054647-A1 | New pharmaceutical combination | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-03-10 | — | — | US | disclosed |
| US-6794392-B1 | Cell differentiation inducer | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-09-21 | — | — | US | disclosed |
| US-20040147569-A1 | Antitumor agents; autoimmune disease; skin disorders; anticancer agents | SCHERING AKTIENGESELLSCHAFT | 2004-07-29 | — | — | US | disclosed |
| WO-2004058234-A2 | PHARMACEUTICAL COMBINATIONS OF PHTHALAZINE VEGF INHIBITORS AND BENZAMIDE HDAC INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-07-15 | — | — | WO | disclosed |
| EP-1437346-A1 | Benzamide derivatives useful as cell differentiation inducers | Schering AG (DE) | 2004-07-14 | — | — | EP | disclosed |
| EP-0847992-B1 | Benzamide derivatives, useful as cell differentiation inducers | SCHERING AG (DE) | 2004-06-23 | — | — | EP | disclosed |
| US-6174905-B1 | AS CARCINOSTATIC AGENT TO A HEMATOLOGIC MALIGNANCY AND A SOLID CARCINOMA | MITSUI CHEMICALS, INC. (JP) | 2001-01-16 | — | — | US | disclosed |
| EP-0847992-A1 | Benzamide derivatives, useful as cell differentiation inducers | Mitsui Chemicals, Inc. (JP) | 1998-06-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147569-A1 | Antitumor agents; autoimmune disease; skin disorders; anticancer agents | MCL1, MYADM, PDCD1 | HDAC1 81/4885HDAC3 807/4885HDAC2 204/4885 |
| US-20050054647-A1 | New pharmaceutical combination | VEGFA, INHA, PGF | HDAC1 976/4885HDAC3 1616/4885HDAC2 1101/4885 |
| US-20070225373-A1 | Zn2Motif-Tethered Short-Chain Fatty Acids as a Novel Class of Histone Deacetylase | HDAC1, BAZ2B, HDAC11 | HDAC1 1/4885HDAC3 6/4885HDAC2 5/4885 |
| US-20110281950-A1 | COMPOSITIONS AND METHODS FOR REDUCING PROLIFERATION AND VIABILITY OF LYMPHOBLASTOID CELLS | HDAC1, HDAC4, HDAC2 | HDAC1 1/4885HDAC3 8/4885HDAC2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.